13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001232621
Total reported value
$2.2B
$2.2B
99 檔
11.3%
During the Q1 2024 filing period, Tang Capital Management LLC (CIK: 0001232621) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.2B across 99 reported positions.
During Q1 2024, Tang Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 8.53% | +0.25% | +2.27% | |
| 2 | EOLS | Evolus Inc | Stock-Other | 6.05% | -0.10% | EXIT | |
| 3 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 5.09% | -4.68% | EXIT | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 3.12% | +0.33% | -31.77% | |
| 5 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.10% | +0.77% | +4.40% | |
| 6 | ALT | Altimmune Inc | Stock-Other | 2.91% | -0.01% | — | |
| 7 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.74% | -0.24% | — | |
| 8 | INBXUSD | Inhibrx Inc | Stock-Other | 2.55% | — | — | |
| 9 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.19% | — | -10.00% | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 2.13% | — | — | |
| 11 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 2.12% | +0.37% | -22.22% | |
| 12 | OTLK | Outlook Therapeutics Inc | Stock-Other | 2.01% | — | — | |
| 13 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.85% | — | +164.00% | |
| 14 | IMNM | Immunome Inc | Stock-Other | 1.85% | — | — | |
| 15 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.84% | — | -2.99% | |
| 16 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.78% | — | +55.00% | |
| 17 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 1.71% | -0.30% | — | |
| 18 | ✓ | Elevation Oncology Inc | Stock-Other | 1.63% | — | -16.57% | |
| 19 | APLT | Applied Therapeutics Inc | Stock-Other | 1.58% | — | — | |
| 20 | TORCEUR | Adicet Bio Inc | Stock-Other | 1.57% | — | +631.14% | |
| 21 | MOR2 | Morphosys AG Adr | Stock-Other | 1.51% | — | — | |
| 22 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.46% | — | -1.53% | |
| 23 | NUVB | Nuvation Bio Inc | Stock-Other | 1.35% | +0.16% | +1.48% | |
| 24 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.34% | — | — | |
| 25 | LENZ | Lenz Therapeutics Inc | Stock-Other | 1.27% | -0.09% | — | |
| 26 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.26% | -0.28% | — | |
| 27 | ZYME | Zymeworks Inc | Stock-Other | 1.20% | — | — | |
| 28 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.08% | — | +190.77% | |
| 29 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.08% | — | -31.82% | |
| 30 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.08% | -0.10% | — | |
| 31 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 1.07% | +0.85% | +272.73% | |
| 32 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.06% | — | -11.76% | |
| 33 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.03% | — | -16.67% | |
| 34 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.01% | — | -25.94% | |
| 35 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.00% | — | +353.58% | |
| 36 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.98% | — | +3.69% | |
| 37 | DCPHEUR | Deciphera Pharmaceuticals In | Stock-Other | 0.98% | — | — | |
| 38 | NVDA | Nvidia CORP | Stock-Tech | 0.94% | — | — | |
| 39 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.85% | +0.06% | — | |
| 40 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.85% | — | -11.09% | |
| 41 | DTIL | Precision Biosciences Inc | Stock-Other | 0.83% | — | — | |
| 42 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.83% | +0.04% | -47.51% | |
| 43 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.83% | — | -45.81% | |
| 44 | BHVN | Biohaven Ltd. | Stock-Other | 0.80% | — | — | |
| 45 | ARVN | Arvinas Inc | Stock-Other | 0.77% | -0.29% | EXIT | |
| 46 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.77% | — | -50.00% | |
| 47 | VNDA | Vanda Pharmaceuticals Inc | Stock-Other | 0.75% | — | +605.77% | |
| 48 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.73% | — | -9.09% | |
| 49 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.69% | — | — | |
| 50 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.68% | — | -25.00% |
According to official SEC Form 13F filings, Tang Capital Management LLC reported a total U.S. public equity portfolio value of $2.2B across 99 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TARS, EOLS, 4XC1) accounted for 11.3% of total reported equity market value during Q1 2024.
During Q1 2024, Tang Capital Management LLC's top holdings by market value included TARS (8.5%)、EOLS (6.0%)、4XC1 (5.1%). The largest single position, TARS, represented 8.5% of total portfolio value.
In Q1 2024, Tang Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.